Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial
Authors:
- Dino AmadoriDADino Amadori
- Massimo AgliettaMAMassimo Aglietta
- Barbara AlessiBABarbara Alessi
- Lorenzo GianniLGLorenzo Gianni
- Toni IbrahimToni Ibrahim
- Gabriella FarinaGFGabriella Farina
- Fernando GaionFGFernando Gaion
- Francesco BertoldoFBFrancesco Bertoldo
- Daniele SantiniDSDaniele Santini
- Roberta RondenaRRRoberta Rondena
- Paola BoganiPBPaola Bogani
- Carla I RipamontiCRCarla I Ripamonti
- 1 June 2013
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 14 (7) , 663-670
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Bisphosphonates as Treatment of Bone MetastasesCurrent Pharmaceutical Design, 2010
- Zoledronic acid and skeletal complications in patients with solid tumors and bone metastasesCancer, 2008
- The bone microenvironment in metastasis; what is special about bone?Cancer and Metastasis Reviews, 2007
- Pathologic fractures correlate with reduced survival in patients with malignant bone diseaseCancer, 2007
- Bisphosphonates: Clinical ExperienceThe Oncologist, 2004
- Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate CancerJNCI: Journal of the National Cancer Institute, 2004
- Health-Related Quality of Life Among Patients With Breast Cancer Receiving Zoledronic Acid or Pamidronate Disodium for Metastatic Bone LesionsMedical Care, 2004
- Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinomaCancer, 2003
- Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasesCancer, 2000
- Skeletal complications of malignancyCancer, 1997